Amundi
VIR icon

Amundi’s Vir Biotechnology VIR Stock Holding History

Amundi’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
15,315
+5,294
+53% +$42.2K ﹤0.01% 1930
2025
Q4 		$60.4K Sell
10,021
-4,559
-31% -$27.1K ﹤0.01% 1826
2025
Q3 		$81.5K Hold
14,580
– – ﹤0.01% 1588
2025
Q2 		$79.2K Sell
14,580
-22,052
-60% -$118K ﹤0.01% 1654
2025
Q1 		$218K Sell
36,632
-9,982
-21% -$88.8K ﹤0.01% 1662
2024
Q4 		$582K Buy
46,614
+32,241
+224% +$254K ﹤0.01% 1536
2024
Q3 		$105K Buy
14,373
+1,506
+12% +$13.1K ﹤0.01% 1769
2024
Q2 		$113K Sell
12,867
-2,413
-16% -$23.1K ﹤0.01% 1689
2024
Q1 		$122K Buy
15,280
+4,417
+41% +$45K ﹤0.01% 1733
2023
Q4 		$111K Hold
10,863
– – ﹤0.01% 1757
2023
Q3 		$90.9K Buy
10,863
+1,100
+11% +$15.7K ﹤0.01% 1772
2023
Q2 		$240K Buy
+9,763
New +$245K ﹤0.01% 1559
2022
Q4 		– Sell
-3,842
Closed -$85K – 1986
2022
Q3 		$85K Hold
3,842
– – ﹤0.01% 1585
2022
Q2 		$110K Hold
3,842
– – ﹤0.01% 1433
2022
Q1 		$88K Hold
3,842
– – ﹤0.01% 1487
2021
Q4 		$145K Hold
3,842
– – ﹤0.01% 1524
2021
Q3 		$167K Hold
3,842
– – ﹤0.01% 1460
2021
Q2 		$182K Buy
+3,842
New +$175K ﹤0.01% 1393

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Amundi's VIR Position: Q1 2026 in Review

Amundi increased its Vir Biotechnology (VIR) stake by 53% in Q1 2026, buying an estimated $42.2K and bringing the position to 15,315 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1930.

Amundi first reported a position in VIR in Q2 2021 and has held it in 18 quarters since. The position peaked at $582K in Q4 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Amundi held 15,315 shares of Vir Biotechnology worth $137K as of Q1 2026.
  • Amundi bought 5,294 Vir Biotechnology shares in Q1 2026, an estimated $42.2K.
  • Vir Biotechnology made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1930 holding.
  • Amundi first reported a position in Vir Biotechnology in Q2 2021 and has held it in 18 quarters since.
  • Amundi's Vir Biotechnology position peaked at $582K in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.